Treosulfan in the treatment of advanced ovarian cancer: results of a German multicenter non-interventional study
Background: Data on routine systemic treatment of patients with ovarian cancer are currently available only to a limited degree. The alkylating agent treosulfan is approved in oral (p.o.) and intravenous (i.v.) form for the treatment of ovarian carcinoma. The present non-interventional study analyze...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 2015
|
| In: |
Anticancer research
Year: 2015, Volume: 35, Issue: 12, Pages: 6869-6875 |
| ISSN: | 1791-7530 |
| DOI: | undefined |
| Online Access: | Verlag, Volltext: http://dx.doi.org/undefined Verlag, Volltext: http://ar.iiarjournals.org/content/35/12/6869 
|
| Author Notes: | Radoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, Thomas Göhler, Peter Klare, Gülten Oskay-Özcelik, Uwe Sauer, Arthur Wischnik, Ursula Vehling-Kaiser, Martin Becker, Ulrich Hutzschenreuter, Andreas Ammon, Elke Heidrich-Lorsbach and Jalid Sehouli |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1584620013 | ||
| 003 | DE-627 | ||
| 005 | 20230427161334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181129s2015 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1584620013 | ||
| 035 | |a (DE-576)514620013 | ||
| 035 | |a (DE-599)BSZ514620013 | ||
| 035 | |a (OCoLC)1341024437 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chekerov, Radoslav |e VerfasserIn |0 (DE-588)1172433216 |0 (DE-627)104120258X |0 (DE-576)514620285 |4 aut | |
| 245 | 1 | 0 | |a Treosulfan in the treatment of advanced ovarian cancer |b results of a German multicenter non-interventional study |c Radoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, Thomas Göhler, Peter Klare, Gülten Oskay-Özcelik, Uwe Sauer, Arthur Wischnik, Ursula Vehling-Kaiser, Martin Becker, Ulrich Hutzschenreuter, Andreas Ammon, Elke Heidrich-Lorsbach and Jalid Sehouli |
| 264 | 1 | |c December 2015 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.11.2018 | ||
| 520 | |a Background: Data on routine systemic treatment of patients with ovarian cancer are currently available only to a limited degree. The alkylating agent treosulfan is approved in oral (p.o.) and intravenous (i.v.) form for the treatment of ovarian carcinoma. The present non-interventional study analyzed the clinical use of treosulfan in Germany, evaluating the mode of application, toxicity, and response and survival rate. Patients and Methods: Two hundred and forty-eight ovarian cancer patients in 57 Centers, who received treosulfan mainly either i.v. (5,000-8,000 mg/m2 d1, q21d or q28d) or p.o. (400-600 mg/m2 d1-14 or 21, q28d) for at least one therapy cycle were evaluable and were included in the study. Results: With a median age of 70 years (range=36-92 years), predominantly elderly patients received treosulfan treatment. Most participants presented serous histology (131, 52.8%) and advanced-stage FIGO III (122, 49%) or IV (55, 22%) disease. Median ECOG status was 1 (range=0-2), whereas cardiac co-morbidity was common (31%). Treosulfan was usually administered as second- (26%), third- (21%) or fourth-line (17%) therapy. Two hundred and one patients received i.v. and 47 p.o. treatment. The most common reason for dose modifications was due to hematological toxicity (46%). The main reason for a therapy discontinuation was progressive disease (38.5%). Response was observed in 25.8% of participants, disease stabilization in 28.6 % and progress in 45.6%. The median progression-free and overall survival was 196 and 405 days, respectively. Conclusion: In predominantly elderly and heavily pre-treated patients with recurrent ovarian cancer, treosulfan featured a clinical relevant efficacy and well-manageable, mostly hematological, toxicity, which resulted in a positive therapeutic index. | ||
| 650 | 4 | |a elderly | |
| 650 | 4 | |a non-interventional study | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a Treosulfan | |
| 700 | 1 | |a Wischnik, Arthur |d 1952- |e VerfasserIn |0 (DE-588)1067478655 |0 (DE-627)818787961 |0 (DE-576)426689615 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004 |g 35(2015), 12, Seite 6869-6875 |h Online-Ressource |w (DE-627)387478493 |w (DE-600)2145376-7 |w (DE-576)358408717 |x 1791-7530 |7 nnas |a Treosulfan in the treatment of advanced ovarian cancer results of a German multicenter non-interventional study |
| 773 | 1 | 8 | |g volume:35 |g year:2015 |g number:12 |g pages:6869-6875 |g extent:7 |a Treosulfan in the treatment of advanced ovarian cancer results of a German multicenter non-interventional study |
| 856 | 4 | 0 | |u http://dx.doi.org/undefined |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ar.iiarjournals.org/content/35/12/6869 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181129 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1067478655 |a Wischnik, Arthur |m 1067478655:Wischnik, Arthur |d 60000 |d 61300 |e 60000PW1067478655 |e 61300PW1067478655 |k 0/60000/ |k 1/60000/61300/ |p 8 | ||
| 999 | |a KXP-PPN1584620013 |e 303595819X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"issn":["1791-7530"],"eki":["387478493"],"zdb":["2145376-7"]},"origin":[{"publisherPlace":"Kapandriti, Attiki, Greece","publisher":"International Institute of Anticancer Research","dateIssuedKey":"2004","dateIssuedDisp":"2004-"}],"name":{"displayForm":["International Institute of Anticancer Research"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"international journal of cancer research and treatment","title":"Anticancer research","title_sort":"Anticancer research"}],"part":{"extent":"7","text":"35(2015), 12, Seite 6869-6875","volume":"35","issue":"12","pages":"6869-6875","year":"2015"},"pubHistory":["Nachgewiesen 24.2004 -"],"recId":"387478493","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 26.02.13"],"disp":"Treosulfan in the treatment of advanced ovarian cancer results of a German multicenter non-interventional studyAnticancer research"}],"physDesc":[{"extent":"7 S."}],"name":{"displayForm":["Radoslav Chekerov, Gabriele Kaltenecker, Dietmar Reichert, Thomas Göhler, Peter Klare, Gülten Oskay-Özcelik, Uwe Sauer, Arthur Wischnik, Ursula Vehling-Kaiser, Martin Becker, Ulrich Hutzschenreuter, Andreas Ammon, Elke Heidrich-Lorsbach and Jalid Sehouli"]},"id":{"eki":["1584620013"]},"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"December 2015"}],"recId":"1584620013","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 29.11.2018"],"person":[{"display":"Chekerov, Radoslav","roleDisplay":"VerfasserIn","role":"aut","family":"Chekerov","given":"Radoslav"},{"given":"Arthur","family":"Wischnik","role":"aut","roleDisplay":"VerfasserIn","display":"Wischnik, Arthur"}],"title":[{"title":"Treosulfan in the treatment of advanced ovarian cancer","subtitle":"results of a German multicenter non-interventional study","title_sort":"Treosulfan in the treatment of advanced ovarian cancer"}]} | ||
| SRT | |a CHEKEROVRATREOSULFAN2015 | ||